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ABSTRACT
Introduction: The REGAL (RSV Evidence—a
Geographical Archive of the Literature) series
provide a comprehensive review of the pub-
lished evidence in the field of respiratory syn-
cytial virus (RSV) in Western countries over the
last 20 years. The objective of this fifth publi-
cation was to determine the long-term respira-
tory morbidity associated with RSV lower
respiratory tract infection (RSV LRTI) in early
life.
Methods: A systematic review was undertaken
for articles published between January 1, 1995
and December 31, 2015. This was supplemented
by inclusion of papers published whilst drafting
the manuscript. Studies reporting data on the
incidence and long-term wheezing and asthma
following RSV LRTI in early life were included.
Study quality and strength of evidence (SOE)
were graded using recognized criteria.
Results: A total of 2337 studies were identified
of which 74 were included. Prospective, epi-
demiologic studies consistently demonstrated
that RSV LRTI is a significant risk factor for
on-going respiratory morbidity characterized by
transient early wheezing and recurrent wheez-
ing and asthma within the first decade of life
and possibly into adolescence and adulthood
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(high SOE). RSV LRTI was also associated with
impaired lung function in these children (high
SOE). Respiratory morbidity has been shown to
result in reduced quality of life and increased
healthcare resource use (moderate SOE). The
mechanisms through which RSV contributes to
wheezing/asthma development are not fully
understood, but appear to relate to the viral
injury, preexisting abnormal lung function and/
or other factors that predispose to wheezing/
asthma, including genetic susceptibility, altered
immunology, eosinophilia, and associated risk
factors such as exposure to environmental
tobacco smoke (high SOE).
Conclusion: There is growing evidence that
RSV LRTI in early childhood is associated with
long-term wheezing and asthma and impaired
lung function. Future research should aim to
fully elucidate the pathophysiological mecha-
nisms through which RSV causes recurrent
wheezing/asthma.
Keywords: Asthma; Bronchial hyperreactivity;
Bronchiolitis; Lower respiratory tract infection;
Lung function; Recurrent wheezing; Respiratory
morbidity; Sensitization; Wheezing
INTRODUCTION
Respiratory syncytial virus (RSV) is a leading
cause of lower respiratory tract infection (LRTI)
in children worldwide, with severe infection
resulting in hospitalization and considerable
morbidity [1, 2]. Previous infection with RSV
does not convey persistent immunity and rein-
fection is common, though the severity of
infection tends to decrease with increasing age
[3]. There are well-characterized risk factors for
RSV hospitalization (RSVH) including prema-
turity, chronic lung disease (CLD) and congen-
ital heart disease (CHD) [4–8]; however, the
majority of children hospitalized for RSV LRTI
are previously healthy and have no risk factors
for severe disease [7, 9]. In addition to the acute
burden of RSV, epidemiological data suggest
that RSV infection in the first 3 years of life is
associated with long-term respiratory morbid-
ity, such as recurrent wheezing and asthma,
decreased lung function, and possibly allergic
sensitization [10–12]. Such respiratory morbid-
ity may persist into early adulthood [12, 13].
These long-term effects may reduce quality of
life (QoL) and increase healthcare resource uti-
lization [14, 15].
The etiological link between RSV infection
and the development of asthma has long been
debated. It is unclear whether severe RSV LRTI
causes wheezing, or if genetic predisposition or
other environmental risk factors increase the
propensity for an exaggerated response to RSV
[16]. It has been proposed that both of these
pathways may be relevant, and that there may
be differential effects based on the child’s atopic
predisposition and the specific viral genotype
[2]. It remains unclear, however, which children
hospitalized for severe RSV infection will
develop recurrent wheezing and/or asthma later
in life. Predicting which children are at risk for
long-term respiratory problems could identify
specific populations who would benefit from
early targeted interventions.
The primary objective of REGAL (RSV Evi-
dence—a Geographical Archive of the Litera-
ture) was to carry out a series of systematic
reviews and then to assess, quantify, summarize
and grade the evidence base for severe RSV
infection in Western societies over the past
20 years [17–20]. REGAL was undertaken by an
expert panel, comprising neonatologists, pedi-
atricians, pediatric infectious disease specialists,
pediatric cardiologists and pediatric pulmo-
nologists from the United States, Canada and
Europe. This paper, which represents the fifth in
a series of seven publications covering a range of
topics on RSV disease, identifies and describes
the incidence, risk factors and long-term effects
of respiratory morbidity and allergic sensitiza-
tion after RSV LRTI in early life.
METHODS
The primary objective of REGAL was to address
seven specific research questions relating to RSV
covering: epidemiology [17]; premature infants
[18]; CLD [19]; CHD [20]; special populations
(e.g. Down syndrome); prevention and future
management; and long-term respiratory mor-
bidity, the focus of this paper. The systematic
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reviews undertaken to answer each research
question all used the same broad methodology,
which has been described elsewhere [17]. The
full protocol and generic search terms for the
systematic reviews are available as part of the
online supplement. To ensure that the literature
search was manageable, only studies conducted
in Western countries, which we defined as the
United States, Canada, and Europe (including
Turkey and the Russian Federation), were
included.
In this systematic literature review, we
sought to answer the following question: What
is the nature, incidence and impact on long-
term respiratory morbidity after RSV LTRI in
early life in Western countries, specifically early
and late wheeze? The search for this systematic
review included studies published between
January 1, 1995 and December 31, 2015
indexed in PubMed, EMBASE, the Cochrane
Library, and clinicaltrials.gov. The target popu-
lation was children who were hospitalized for
RSV LRTI in early childhood (first 2–3 years of
life) and subsequently developed recurrent
wheezing/asthma in later life. RSVH was defined
as hospital admission for lower respiratory tract
symptoms (deep or wet chest cough, wheezing,
hoarseness, stridor, shortness of breath) and
either a positive enzyme immunoassay or a
positive direct immunofluorescence assay for
RSV infection of epithelial cells in nasopharyn-
geal secretions, a positive polymerase chain
reaction test or a positive viral culture for RSV.
The following general terms and limits were
used in the literature search: ‘‘RSV’’ OR ‘‘respi-
ratory syncytial virus’’ AND ‘‘hospital’’ OR ‘‘ad-
mission’’ OR ‘‘admitted’’ AND ‘‘respiratory
morbidity’’ OR ‘‘respiratory sequelae’’ OR
‘‘complication’’ OR ‘‘manifestation’’ OR ‘‘conse-
quence’’ OR ‘‘long-term’’ OR ‘‘long term’’ OR
‘‘outcome’’ OR ‘‘wheezing’’ OR ‘‘wheeze’’ OR
‘‘asthma AND ‘‘limits: human, child
(birth-18 years)’’. ‘‘Bronchiolitis’’ and ‘‘pneu-
monia’’ were captured as part of the Medical
Subject Headings (MeSH) terms. We recognize
that, while some relevant articles might have
been missed by the searches, the combined
Boolean operators ‘‘AND’’ and ‘‘OR’’ of the key
text words and index terms should have pre-
cisely captured the vast majority of relevant
citations which were pertinent for this evi-
dence-based review. The search results were
supplemented by a review of the bibliographies
of key articles for additional studies and inclu-
sion of relevant abstracts presented at key
meetings. Other significant studies of the target
population, published during the drafting of
the manuscript, were also included in the
review, as identified by the authors.
Definition of Asthma and Recurrent
Wheezing
A variety of definitions of wheezing and asthma
have been used in studies of RSV. A formal
diagnosis of asthma is outlined in the Interna-
tional Statistical Classification of Diseases and
Related Health Problems (ICD) 10 code of J45 or
an International Classification of Primary Care
(ICPC) code of R96 [21, 22]. The ICPC also
provides a specific code for wheezing: R03. For
completeness, we have included all relevant
studies in the review and provided the defini-
tions used within the summary tables. For
future studies, we would recommend that ‘cur-
rent asthma’ be defined as a history of asthma
diagnosed by a physician, plus asthma symp-
toms or medication (beta-mimetics or inhaled
corticosteroids) use in the last 12 months [23].
For this review, recurrent wheezing was defined
as 3 or more wheezing episodes within
12 months, reported by either a physician
(preferably) or a patient [14].
Outcomes of Interest
The outcomes of interest for this review
included:
(i) asthma, recurrent wheezing and allergic
sensitization rates after RSV LRTI in early
life,
(ii) lung function after RSV LRTI in early life,
(iii) the relationship between RSV LRTI and
subsequent development of clinical
allergy or allergic sensitization, and
(iv) factors associated with the development
of recurrent wheezing/asthma after RSV
LRTI in early life.
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Evaluation of Data
Included publications were graded according to
the Oxford Centre for Evidence-Based Medicine
Levels of Evidence [24, 25] (Supplementary
Material 1—REGAL Protocol). For each study,
we conducted a risk of bias assessment using the
RTI Item Bank (score of 1 = very high risk of
bias; score of 12 = very low risk of bias) for
observational studies [26]. No quantitative data
synthesis was conducted due to heterogeneity
between studies in terms of design, patient
populations, RSV testing, recording and avail-
ability of outcomes, and differences in clinical
practice between countries and over time.
Compliance with Ethics Guidelines
The analysis in this article is based on previ-
ously published studies and does not involve
any new studies of human subjects performed
by any of the authors.
RESULTS
Articles Selected
From a total of 2337 publications, 74 studies
were included in the final review: 58 identified
from the database searches and a further 16
from reference lists/other sources (Fig. 1). Data
extraction tables for all 74 studies, including
evidence grades and risk of bias assessments can
be found in the online supplement.
RSV LRTI in Early Life and the Risk
of Developing Recurrent Wheezing/
Asthma
Evidence from an increasing number of studies
suggests a strong association between severe
RSV LRTI in children aged\3 years and the
subsequent development of recurrent wheez-
ing/asthma in later life [10–14, 23, 27–44]. Due
to differences in study design and methodology,
Fig. 1 PRISMA ﬂow diagram: Incidence and impact of long-term respiratory morbidity associated with RSV LRTI in early
life
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definitions of wheezing/asthma used (including
whether asthma is current/active), patient
populations and length of follow-up, the
reported rates of recurrent wheezing and
asthma vary considerably across studies
(Table 1). Following RSV LRTI in early child-
hood (B3 years old), recurrent wheezing rates of
4–47% and asthma rates of 8–76% have been
reported in studies with up to 25 years fol-
low-up (average follow-up 6–8 years)
[14, 28, 33, 42].
Several studies have indicated that, for many
children, RSV-associated wheezing might be a
transient event, diminishing over time, and
may be even disappearing to background levels
in early adolescence [10, 11, 28, 30, 31, 45]. In
the Tucson Children’s Respiratory Study, car-
ried out in the United States, an increased risk
of subsequent wheeze in children aged\3 years
with RSV LRTI (most of whom were not hospi-
talized) was observed until the age of 11 years,
but, by the time these children were 13 years of
age, the association between wheeze and RSV
LRTI was no longer significant [30]. Sigurs et al.
followed a cohort of 47 Swedish infants
aged\12 months hospitalized for severe RSV
infections and 93 matched controls at ages 3, 7,
13 and 18 years [10, 11, 28, 29]. Up to age 7,
recurrent wheezing was significantly more fre-
quent in the RSVH group compared with con-
trol subjects (13.0% vs. 0%, respectively;
P\0.001) [10], though the difference, albeit
still higher in the RSVH group, was not signifi-
cant by age 13 (30% vs. 16.3%; P = 0.093) [11].
At 18 years, results specifically for recurrent
wheezing were not presented, but when recur-
rent wheezing was combined with asthma, rates
were significantly higher for those with a his-
tory of RSVH than with controls (39% vs. 9%,
respectively; P = 0.001) [29]. Another long-term
study reported RSV-associated wheezing to per-
sist at[25 years of age [35% vs. 16.3% of con-
trols; odds ratio (OR) 2.79, 95% confidence
interval (95% CI) 1.15–6.75] [13]. Hence, whilst
there is evidence that RSV-associated wheezing
tends to diminish with time, it can persist into
adulthood in some patients.
A number of prospective studies have
demonstrated that RSV LRTI in childhood is an
important risk factor for asthma in early
adulthood [10, 12, 13, 29, 32]. In the study by
Sigurs et al. [10], multivariate analysis at the
7-year follow-up showed that RSV bronchiolitis
had the highest independent risk ratio for
asthma (OR, 12.7; 95% CI, 3.4–47.1). This was
reconfirmed in the 18-year analysis, where
RSVH was an independent risk factor for current
asthma/recurrent wheeze (OR, 6.2; 95% CI,
2.0–19.2; P\0.001) and current asthma alone
(OR, 7.2; 95% CI, 2.1–23.9; P\0.001) [29].
Current asthma was reported in 33% of RSVH
subjects and 7% of controls at up to 18 years of
age (P\0.001) [29]. The RSV Bronchiolitis in
Early Life study (REBEL) also supports the link
between RSV LRTI in childhood and physi-
cian-diagnosed asthma by school age [40]. In
this prospective cohort study, nearly half (48%)
of the children who developed severe RSV LRTI
in the first year of life were diagnosed with
childhood asthma by 7 years of age. The authors
identified that greater levels of nasal epithelial
expression of the chemokine CCL5 at the time
of bronchiolitis were strongly predictive of
physician-diagnosed asthma by the 7th birth-
day [40]. Other studies have demonstrated that
RSVH at\2 years of age is a significant risk fac-
tor for adulthood asthma at 18–20 years [12]
and[25 years [13]. Based on the findings of a
retrospective study analyzing cohort data from
264,010 infants born in the United States
between 1995 and 2003, it was proposed that
13% of asthma cases could be prevented by
eliminating infant bronchiolitis during the RSV
season [37].
Whilst it can be seen from the above that
RSVH in early infancy is associated with an
increased risk of long-term respiratory morbid-
ity, other respiratory viruses, particularly rhi-
novirus, might be associated with a
comparatively greater risk of wheezing/asthma
[33, 46–49]. In a study from Finland, Koponen
et al. [33] reported that the risk of asthma was
lower after RSV bronchiolitis than after bron-
chiolitis caused by other viruses (rhinovirus,
influenza A virus, parainfluenza type 3 virus,
adenovirus, human metapneumovirus, and
unknown etiology) in infants hospitalized
within the first 6 months of age (8.2% vs. 24%
in non-RSV patients; P = 0.01) [33]. Other
studies from Finland undertaken in the early
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2000s [50, 51] suggest that the risk of early
school-age asthma following RSVH might be of
a similar order or slightly lower than that seen
in children hospitalized with wheezing with no
evidence of RSV (8–50% vs. 45–57%, respec-
tively, depending on age at admission) [51].
Valkonen et al. [47] reported that Turkish chil-
dren hospitalized with bronchiolitis caused by
viruses other than RSV develop recurrent
wheezing at substantially higher rates than do
children with RSV-associated bronchiolitis. The
risk of developing recurrent wheezing was sig-
nificantly increased in the non-RSV group
within the first 2 years [relative risk (RR), 2.9;
95% CI, 1.7–5.1] and 3 years (RR, 3.4; 95% CI,
2.0–5.7) after hospitalization [47]. A more
recent study from Spain found that children
aged C4 years with a history of rhinovirus,
metapneumovirus or bocavirus associated
bronchiolitis had more hospital admissions for
respiratory conditions than RSV-positive chil-
dren for respiratory conditions (30% vs. 17%,
respectively; P = 0.075), persistent asthmatic
symptoms (25% vs. 7%; P = 0.003), and asth-
matic exacerbations in the last year (40% vs.
22%; P = 0.023) [48]. Studies have indicated
that the differences in risk of wheezing/asthma
following RSV versus non-RSV bronchiolitis is
not associated with differences in age, seasonal
factors, prematurity, day-care attendance, ato-
pic dermatitis, allergic sensitization, pulmonary
function, smoke exposure, sex, or family history
of asthma/allergic rhinitis [47–49].
The risk of asthma after bronchiolitis may be
related to the severity of the first episode
[49, 52, 53]. In a prospective study by Carroll
et al. [52], 18% of children with clinically sig-
nificant bronchiolitis during infancy accounted
for 31% of children with early childhood
asthma. In addition, the level of healthcare
utilization during the bronchiolitis episode
correlated with the risk of subsequent asthma,
with the greatest risk of asthma following
bronchiolitis hospitalization. Relative to chil-
dren with no history of infant bronchiolitis, the
adjusted ORs for asthma were 1.86 (95% CI,
1.74–1.99), 2.41 (2.21–2.62) and 2.82
(2.61–3.03) in the Outpatient, Emergency
Department, and Hospitalization groups,
respectively [52]. Al-Shawwa et al. [49]T
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evaluated the potential effect of severity of RSV
LRTI on subsequent wheezing in 155 chil-
dren\2 years of age. Again, hospitalized
patients were more likely to have recurrent
wheezing compared with non-hospitalized
patients (OR 2.84; 95% CI, 1.24–6.50) [49].
Long-term Respiratory Morbidity
in Specific High-risk Groups
Premature Infants
Infants born prematurely are at risk of RSV-re-
lated sequelae, including recurrent wheezing
[14, 39, 54–57]. Data from a prospective study
by Greenough et al. [56] demonstrated that
chronic respiratory morbidity occurs in preterm
infants born between 32 and 35 weeks’ gesta-
tional age (wGA), regardless of whether their
RSV infection required hospitalization. Escobar
et al. [38] retrospectively studied 72,602 infants
born at C32 wGA. In total, 1.74% had a con-
firmed RSV infection (0.69% were hospitalized
and 1.05% were treated as an outpatient).
Across all children, the prevalence of recurrent
wheezing decreased over time from 5.6% during
the second year of life to 4.7% during the fifth
year of life. Three important risk factors (RSV
disease in the first year of life, moderate pre-
maturity and exposure to supplemental oxygen
in the neonatal period) emerged to be signifi-
cantly associated with the development of
recurrent wheezing during the fifth year of life.
The adjusted OR for prolonged RSVH was 2.59
(95% CI, 1.49–4.50) [38]. Similarly, data from
the SPRING study [14], a multicenter, observa-
tional, nested, case–control study undertaken in
Spain, showed a decline in the incidence of
wheezing with age. While the incidence of
recurrent wheezing was higher in cases than in
controls for each individual year of follow-up,
the difference remained statistically significant
only during the first 3 years of life (Table 2).
However, when considering the overall pro-
portion of cases and controls that experienced
recurrent wheezing through 6 years of age, this
was significantly greater in the former than the
latter (46.7% vs. 27.4%, respectively; P = 0.001).
Multivariate analysis revealed that RSVH was
the most important factor for wheezing
(recurrent wheezing: OR, 4.40; 95% CI,
2.82–6.86; P\0.001; severe wheezing: OR, 4.31;
95% CI, 2.78–6.68; P\0.001) [14].
A 12-month follow-up of the French CAS-
TOR (Comparison of the rAte of hoSpitalization
for RSV bronchioliTis between preterm infants
born at 32 weeks’ gestational age or less without
brOnchopulmonary dysplasia and full-teRm
infants) study cohort was undertaken to evalu-
ate the respiratory morbidity of preterm
infants\33 wGA without BPD during the sub-
sequent 12-month period [54]. In this study,
242 preterm infants were compared with 201
full-term infants (39–41 wGA). Preterm infants
had increased respiratory morbidity during the
follow-up period compared with full-term
infants; they were more likely to have wheezing
(21% vs. 11%, P = 0.007) and recurrent wheez-
ing (C3 episodes of within 12 months; 4% vs.
1%, P = 0.049). The 17 infants (14 preterms, 3
full-terms) who had been hospitalized for
RSV-confirmed LRTI during their first RSV sea-
son had significantly more wheezing episodes
during the follow-up period than the infants
who had not been hospitalized for RSV con-
firmed LRTI (OR, 4.72; 95% CI, 1.71–13.08;
P = 0.003) [54].
Congenital Heart Disease
Whilst it is well established that children with
CHD are at risk for severe RSV LRTI, limited data
are available on the long-term respiratory mor-
bidity associated with RSVH in early life in this
patient population. In a retrospective study of
3223 children with CHD, 19 (0.6%) and 417
(12.9%) were hospitalized for RSV or LRTI,
respectively, before the age of 2 years [58]. Fif-
ty-nine percent of children with CHD who were
hospitalized for LRTI in infancy were diagnosed
with chronic respiratory morbidity at the age of
10 years, as compared with 31.5% of children
with CHD not hospitalized for LRTI in infancy
[58].
Down Syndrome
Down syndrome is an independent risk factor
for RSVH and severe RSV disease [59]. There are
limited data, however, on long-term respiratory
morbidity associated with RSV LRTI in early life
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in children with Down syndrome. In a com-
bined retrospective/prospective cohort study,
Bloemers et al. [60] found that RSV LRTI did not
significantly contribute to the risk of recurrent
wheeze in children with Down syndrome
(RSVH: 36% vs. non-hospitalized: 30%; not
statistically significant). Similar non-significant
differences were found for parent-reported
recurrent wheeze (42% vs. 32%, respectively)
and physician-diagnosed asthma (11% vs. 9%,
respectively). Physician-diagnosed wheeze,
however, was more common in children with
Down syndrome hospitalized for RSV LRTI than
healthy controls (31% vs. 8%; P = 0.004). The
authors proposed that abnormal lung function
or airway hyper-responsiveness, as well as an
abnormal immunologic status, could play a role
in the development of long-term airway mor-
bidity in children with Down syndrome, irre-
spective of RSV status [60].
Reduced Lung Function
RSV LRTI in early life is associated with reduced
lung function and increased airway reactivity at
school age [11, 12, 30, 36, 61, 62], potentially
extending into adulthood [12]. A prospective
cohort study from the UK reported that viral
LRTIs, regardless of hospitalization, adversely
affect preterm infants’ (\36 wGA) lung function
at 12-month follow-up [63]. Longer-term data
from the UK demonstrated that preterm infants
(\32 wGA) who develop bronchopulmonary
dysplasia (BPD) and are hospitalized for RSV
infection in the first 2 years of life have
significantly worse lung function at 8–10 years
[62]. Similarly, the Tucson Children’s Respira-
tory Study reported that children who had RSV
LRTI before the age of 3 years had decreased
lung function at school age [30]. In a prospec-
tive, 20-year follow-up study from Finland, at
least one abnormal lung function result was
observed in 44% of subjects who developed RSV
LRTI in the first 2 years of life, compared with
31% of controls (P\0.05) [12]. In addition, RSV
LRTI in infancy was an independent risk factor
for lung function abnormality [spirometric air-
way function (FVS; OR, 5.27, 95% CI,
1.60–17.36) and also for decreased forced expi-
ratory volume in 1 s FEV1/FVC (FEV%) and
mid-expiratory flow at 50% of FVC (MEF50),
when these were analyzed separately] [12]. At
the 18-year follow-up of the study by Sigurs
et al. [29], reduced spirometric airway function
[1 s FEV1, ratio of FEV1 to FVC, and forced
expiratory flow at 25–75% FVC (FEF25–75)] was
observed in the RSV cohort compared with
controls. However, in contrast to the previous
studies, a Finnish study indicated a potentially
more restrictive pattern of lung function
abnormality, documented by significantly
decreased FVC values concomitantly with nor-
mal FEV1 values and even elevated FEV1/FVC
values [64]. Finally, another recent study from
Finland observed that less than 1% of 5- to
7-year-old children, hospitalized for bronchi-
olitis caused mainly by RSV at age\6 months,
had persistent lung function reduction [65].
It is unclear whether the abnormalities in
lung function seen at follow-up result from the
Table 2 Incidence of recurrent wheezing years 2–6 in the SPRING studya [14]
Wheezing Year 2 Year 3 Year 4 Year 5 Year 6
RSVb Control RSVb Control RSVb Control RSVb Control RSVb Control
Number of children (%) 41.4 12.1 29.3 15.4 18.5 12.6 15.0 9.3 12.4 9.7
P \0.001 0.001 NS NS NS
OR (95% CI) 5.14 (2.68–9.87) 2.28 (1.41–3.70) 1.58 (0.91–2.75) 1.72 (0.92–3.20) 1.32 (0.68–2.59)
CI conﬁdence interval, NS not statistically signiﬁcant, OR odds ratio, RSV respiratory syncytial virus
a For each individual year of follow-up, the number (proportion) of children with wheezing is shown, utilizing all available
data for that particular year (therefore, the same child may be included in more than 1 year). Recurrent wheezing deﬁned
as C3 episodes of wheezing within 12 months
b RSVH in preterm infants (32–35 weeks’ gestational age) in ﬁrst year of life
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RSV infection itself or reflect premorbid abnor-
mal lung function [62]. Studies from the
Netherlands indicate that both hypotheses may
be involved [66]. The MAKI trial has strongly
implicated RSV infection as an important
mechanism of recurrent wheeze during the first
year of life in such infants [66]. A further study
from the same group proposed that lower lung
function in school-aged children that were
previously hospitalized for RSV LRTI cannot
only be attributed to the RSV infection itself,
but might be partially pre-existent [67].
Factors Associated with the Development
of Recurrent Wheezing/Asthma after RSV
LRTI in Early Life
Risk Factors
Several risk factors associated with the devel-
opment of asthma in children with a history of
RSV LRTI in early life have been proposed by
Cassimos et al. [68]. In this retrospective study,
the development of asthma was independently
associated with male gender [adjusted odds
ratio (aOR), 5.0; 95% CI, 2.2–11.5], breast-feed-
ing\3 months (aOR, 8.4; 95% CI, 3.1–22.4),
living in a home environment with moisture
damage (aOR, 2.9; 95% CI, 1.3–6.3) and/or
tobacco smoke by two or more residents (aOR,
4.9; 95% CI, 1.8–9.2), and sensitization to at
least one aeroallergen (aOR, 7.1; 95% CI,
2.8–18.1). Lung function was significantly lower
in children with RSV LRTI compared to a mat-
ched control group, even in children with a
history of RSV LRTI who were not asthmatic
[68].
The mechanisms underlying the interaction
between RSV LRTI in infancy and active smok-
ing as determinants of asthma in early adult life
are unknown [69]. Further findings from the
Tucson Children’s Respiratory Study indicate
that subjects with RSV LRTI during the first
3 years of life who actively smoke are at
increased risk of having current asthma (95%
CI, 1.2–2.3; P = 0.003) and increased peak flow
variability (amplitude % mean: 10.0% vs. 6.4%;
P = 0.02) in adulthood, as compared with those
who do not smoke [69]. The authors suggest
that their findings support the potential
interactive role of early-life insult by RSV and
subsequent active cigarette smoking on the
development of obstructive lung diseases, such
as asthma and chronic obstructive pulmonary
disease (COPD), in later life [69].
Atopy and Allergy
There are limited and conflicting data on the
association between RSV LRTI in early life and
the subsequent development of clinical allergy
and/or allergic sensitization. Sigurs et al. [10, 11]
demonstrated that RSV severe enough to cause
hospitalization was significantly associated with
the development of allergic sensitization up to
the age of 13 years. Multivariate analyses of
possible risk factors for sensitization showed that
RSV LRTI was a significant independent risk
factor for allergic sensitization (OR, 2.4; 95% CI,
1.1–5.5) [10]. Similarly, Schauer et al. [34] found
RSV LRTI to be the single most important risk
factor for sensitization (OR, 20.66; 95% CI,
3.53–120.75). In the study by Korppi et al. [12],
the presence of asthma, bronchial reactivity, and
lung function abnormalities after RSV infection
in infancy were clearly associated with atopy, as
defined by skin test responses to common
inhaled allergens. Several other studies, however,
did not find an association between RSV infec-
tion and subsequent atopy [30, 31, 41, 70]. Stein
et al. [30] found no link between the incidence of
RSV LRTI in early life and the subsequent
development of atopic sensitization. Henderson
et al. [31] also did not observe a significant
association between RSV LRTI in infancy and
allergic sensitization to aeroallergens at age
7 years. Finally, Strannega˚rd et al. [71] reported
that RSV LRTI may be an important risk factor
for later development of atopic disease, but the
authors could not exclude that bronchiolitis
simply serves as a marker that predicts later de-
velopment of atopy.
Genetic Factors
Not all children exposed to RSV experience
subsequent wheezing, suggesting that genetic
factors may also play a role in this phenomenon
[72]. Several studies have therefore aimed to
identify genetic determinants of recurrent
wheeze after RSV LRTI [72–77].
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Results of a multicenter cohort study by
Schuurhof et al. [73] found that the production
of IL10 by monocytes after RSV infection is
higher in patients with recurrent wheezing than
in patients without wheezing [74]. In a 6-year,
prospective, follow-up study of 101 children
hospitalized for RSV LRTI at B12 months of age,
the IL-13 Gln allele was found to be associated
with late wheezing (OR, 3.27; 95% CI,
1.32–8.06), but not with early wheezing [75].
The IL8 polymorphism was not shown to be
related to either early or late wheezing after RSV
LRTI in this study [75]; however, it was found to
be related to wheezing and RSV LRTI in a study
by Goetghebuer et al. [77]. In a subsequent
study by Ermers et al. [76], the genetic variation
in adaptive immunity genes, and particularly in
IL10 family member genes IL19 and IL20 genes,
seemed to be associated with recurrent wheeze
after RSV LRTI, and perhaps infant wheeze in
the general population. This suggests a role for
IL19 and IL20 cytokines in airway disease.
A more recent study from the United States
demonstrated that rare nonsynonymous vari-
ants contribute to the development of asthma
following severe RSV LRTI in infancy, notably
ADRB2. Torgerson et al. [72] performed pooled,
anonymous, sequencing of coding exons from
131 asthma candidate genes in 182 individuals
(99 European Americans and 83 African Amer-
icans) with severe RSV LRTI in infancy from the
REBEL study [40] for variant discovery, and then
directly genotyped a set of 190 nonsynonymous
variants. Four rare, nonsynonymous variants
were found to be significantly associated with
asthma following severe RSV LRTI, including
single variants in ADRB2, FLG and NCAM1 in
European Americans (P = 4.6 9 10-4,
1.9 9 10-13 and 5.0 9 10-5, respectively), and
NOS1 in African Americans (P = 2.3 9 10-11)
[72]. Additional studies are needed to confirm
these associations and determine the functional
consequences of these genetic variants.
Three population-based studies of twins,
undertaken in Denmark utilizing bronchiolitis
information from patient registries, assessed
causality between RSV infection in infancy and
childhood asthma [16, 78, 79]. Thomsen et al.
[78] reported that RSV infection severe enough
to require hospitalization did not appear to
cause asthma but was an indicator of the
genetic predisposition to asthma. Stensballe
et al. [79] reported that asthma hospitalization
after RSVH was increased as much as six- to
eight-fold during the first 2 months after RSVH
but not 1 year later. A further study of 37
monozygotic twin pairs discordant for severe
RSV bronchiolitis in infancy indicated no dif-
ferential effect of severity of RSV infection on
the development of asthma [16].
Altered Immunology
One of the specific characteristics of asthma is
an imbalance in Th1- and Th2-predominant
immune responses [80]. Castro et al. [80]
hypothesized that severe RSV infection result-
ing in bronchiolitis may stimulate a persistent
Th2 response profile with elevated IL4 and IL13
production at 6 years of age in those children
who developed asthma. Two hundred and six
previously healthy infants hospitalized for a
first episode of RSV LRTI were enrolled into the
REBEL cohort study and followed prospectively
through 6 years of age. Th1 cytokines tended to
decrease over time after initial severe RSV
bronchiolitis and Th2 cytokines tended to
increase over time, but these patterns were
unrelated to asthma and allergy outcomes. No
significant difference in Th1 or Th2 cytokine
production at the initial RSV infection was
observed in those who developed asthma or
allergic sensitization by 6 years of age as com-
pared to those who did not. Furthermore, the
production of Th2 cytokines relative to Th1
cytokines, represented by the ratio of IL4: IFN-c,
was not different in those who developed
asthma compared to those who did not. Th1
cytokines tended to decrease over time after
initial severe RSV bronchiolitis and Th2
cytokines tended to increase over time but these
patterns were unrelated to asthma and allergy
outcomes [80].
Plasmacytoid dendritic cells play a crucial
role in antiviral immunity and promoting Th1
polarization, possibly protecting against devel-
opment of allergic disease [81]. Silver et al. [81]
showed that children with a history of severe
RSV LRTI in early life and physician-diagnosed
asthma by age 6 years appear to have a relative
deficiency of plasmacytoid dendritic cells in
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peripheral blood compared to those who were
not diagnosed with asthma. Further data from a
recent prospective study demonstrated that
children with recurrent wheezing following
severe RSV LRTI had a higher proportion of
nasal plasmacytoid dendritic cells, which may
reflect a heightened antiviral response in the
airway leading to the subsequent development
of asthma [82]. Further studies are therefore
needed to confirm these findings.
Researchers have also evaluated the rela-
tionship between viral load in infants hospital-
ized for RSV and recurrent wheezing later in
childhood. Nenna et al. [83] observed higher
RSV-RNA load and significant correlations
between RSV-RNA load and higher inter-
feron-k1/2/3 levels in children previously hos-
pitalized for RSV LRTI and diagnosed with
recurrent wheezing at 3 years follow-up.
Eosinophilia
Several studies have shown that eosinophilia at
the time of bronchiolitis is associated with a
higher risk of developing persistent wheezing in
later childhood [84–87]. Calvo Rey et al. [84]
reported that eosinophil values of[1% during
an episode of acute bronchiolitis in infancy was
associated with a higher risk of developing
persistent wheezing in the first 5 years of life.
Ehlenfield et al. [85] retrospectively studied 43
infants hospitalized with RSV LRTI
at B18 months old. Of children who had eosi-
nophilia with RSV LRTI, 56% had persistent
wheezing at 7 years of age compared with 22%
without detectable eosinophilia with RSV LRTI
(P = 0.045) [84]. In a further study, Pifferi et al.
[86] observed significantly higher serum eosi-
nophil cationic protein levels (P\0.001) at
enrolment in infants with RSV LRTI who
developed persistent wheezing 5 years later
compared with subjects who did not develop
late wheezing. Similarly, Kristja´nsson et al. [87]
reported that a high level of urinary eosinophil
protein X appeared to increase the risk of future
wheezing in children hospitalized for RSV LRTI.
Maternal Antibody
A case–cohort study undertaken in Denmark
examined the influence of maternally derived
RSV neutralizing antibodies on the risk of RSVH
and recurrent wheeze using data from The
Danish National Birth Cohort and the RSV
Database [88]. Stensballe et al. [88] identified
2562 children with RSVH and 6153 children
with recurrent wheeze. One of the main find-
ings of the study was that the titer of maternally
derived RSV neutralizing antibodies in cord
blood was associated with an increased risk of
recurrent wheeze in children both with and
without RSVH [88].
Long-term Respiratory Morbidity
and Impact on Quality of Life and Cost
of Care
RSV LRTI is associated with subsequent decreased
QoL and increased healthcare costs [14, 15, 41],
although data remain limited. In the SPRING
study [14], the respiratory subscale QoL of the
preschool children Quality of Life questionnaire
(TAPQOL) was significantly lower (P = 0.001)
through 6 years of age in preterm infants born
32–35 wGA hospitalized for RSV infection in the
first year of life than in controls. Backman et al.
[41] also reported that, on average, former RSV
patients had a lower respiratory health-related
quality of life (HRQoL) on the St George’s Respi-
ratory Questionnaire (components: symptoms,
activity, impact), at 28–31 years of age than
population-based controls. The difference was
mainly seen in the symptoms score (P = 0.005)
[41]. In an earlier study, Bont et al. [15] reported
that HRQoL at 3 years of age was attributed to
post-bronchiolitis wheezing, but not to pre-ex-
istent risk factors, such as age, gender and pre-
mature birth. In addition to these studies, two
further studies from Norway demonstrated that
being hospitalized for acute bronchiolitis
(specific virus not stated) in infancy was signifi-
cantly associated with later reduced QoL and that
disease severity appeared to negatively influence
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the QoL of the infants and the parental percep-
tion of the child’s health 9 months later [89, 90].
Healthcare resource utilization was signifi-
cantly higher (P\0.001) through 6 years of age
in cases than controls in the SPRING study [14].
Greenough et al. [91] reported that preterm
infants who had had CLD had a greater number
of outpatient attendances for respiratory prob-
lems (mean 2.52 vs. 0.85; P = 0.007). In addi-
tion, the cost of care was significantly greater for
outpatient attendances, including those for
respiratory problems [91]. A further study by
Greenough et al. [62], that enrolled the same
cohort of children, found that those who were
hospitalized for RSV in the first 2 years after
birth had more outpatient attendances and a
greater related cost of care between the ages of
5–7 and worse lung function than children not
admitted in the first 2 years for a respiratory
cause. Healthcare utilization, however,
decreased with increasing postnatal age regard-
less of RSVH status [61].
Limitations
There are several key limitations of this review
that should be recognized, most notably the
variability in defining wheeze and asthma
between studies, which restricts cross-study
comparisons. Allied to this are the differences in
frequency and length of follow-up between
studies and the relatively limited amount of
prospective data beyond 7–8 years after the
index RSVH. Differences in study populations in
terms of the presence of underlying comor-
bidities and prematurity, for example, also
complicate interpretation of the results. The
confounding influence of co-infections, which
were infrequently documented in studies,
might also in part account for discrepancies in
findings among studies. Improvements over
time in both medical and surgical practice and
RSV surveillance may also influence interpreta-
tion of the results.
Key statements/ﬁndings Level of evidencea
There is increasing evidence that RSV LRTI in early life is a signiﬁcant risk factor for subsequent
recurrent wheezing/asthma, persisting at least through early childhood
Recurrent wheezing rates of 4–47% and asthma rates of 8–76% have been reported in studies
with up to 25 years follow-up (average follow-up 6–8 years)
Level 1
(Level 1 studies: n = 21;
Risk of biasb: very low)
RSV LRTI in early life is associated with reduced lung function and increased airway reactivity
Abnormalities reported for spirometric airway function include reduced FEV1, FEV1/FVC, and
FEF25–75
Level 1
(Level 1 studies: n = 8;
Risk of biasb: very low)
RSV-related respiratory morbidity may be related to a combination of the viral insult, preexisting
abnormal lung function and/or other factors predisposing for wheezing/asthma
Other factors include: genetics (e.g. increased production of IL10), altered immunology (e.g.,
altered plasmacytoid dendritic cell levels), eosinophilia, transfer of maternally derived RSV
antibody, and other risk factors (e.g., tobacco smoke exposure)
Level 1
(Level 1 studies: n = 17;
Risk of biasb: very low)
There is conﬂicting evidence on the association between RSV LRTI in early life and the
subsequent development of clinical allergy and/or allergic sensitization
Level 1
(Level 1 studies: n = 7;
Risk of biasb: very low)
RSV LRTI is associated with decreased quality of life and increased healthcare costs, although
data are limited
Level 1
(Level 1 studies: n = 6;
Risk of biasb: very low)
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CONCLUSIONS
There is a growing body of evidence to suggest
that RSV LRTI, regardless of hospitalization
status, is a significant risk factor for on-going
respiratory morbidity characterized by transient
early wheezing and recurrent wheezing within
the first decade of life and possibly into adult-
hood. These infants are also at increased risk of
reduced pulmonary function and a higher risk
or predisposition to asthma and allergies. The
increased respiratory morbidity may lead to a
reduced QoL and increased health care costs. It
still remains unclear, however, whether RSV
LRTI causes respiratory morbidity and/or serves
as a marker for those infants genetically pre-
disposed to develop asthma or wheezing. Fur-
ther prospective, follow-up studies are needed
to clarify the risk factors and long-term respi-
ratory outcome of children hospitalized for
severe RSV LRTI. Future research should aim to
elucidate the pathophysiological mechanisms
through which RSV LRTI causes recurrent
wheezing/asthma.
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